Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Heine, Renaud, Thielen, Frederick W., Koopmanschap, Marc, Kersten, Marie José, Einsele, Hermann, Jaeger, Ulrich, Sonneveld, Pieter, Sierra, Jorge, Smand, Carin, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051992/
https://www.ncbi.nlm.nih.gov/pubmed/33880433
http://dx.doi.org/10.1097/HS9.0000000000000524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051992/
https://www.ncbi.nlm.nih.gov/pubmed/33880433
http://dx.doi.org/10.1097/HS9.0000000000000524

Ejemplares similares